Next Article in Journal
Celiac Disease: Diagnostic Standards and Dilemmas
Next Article in Special Issue
Puzzle Pieces: Neural Structure and Function in Prader-Willi Syndrome
Previous Article in Journal
Factors Associated with Post-Progression Survival in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
Previous Article in Special Issue
Growth Hormone Therapy in Adults with Prader-Willi Syndrome
Article Menu

Export Article

Open AccessReview
Diseases 2015, 3(2), 78-85; doi:10.3390/diseases3020078

Medication Trials for Hyperphagia and Food-Related Behaviors in Prader–Willi Syndrome

1
Department of Pediatrics, Division of Endocrinology, University of Florida College of Medicine, 32607 Gainesville, FL, USA
2
Department of Medicine, University of Alabama at Birmingham, 35294 Birmingham, AL, USA
3
Foundation for Prader-Willi Research, 91789 Walnut, CA, USA
4
Prader-Willi syndrome Association USA, 34238 Sarasota, FL, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Danny Camfferman
Received: 31 March 2015 / Revised: 20 May 2015 / Accepted: 21 May 2015 / Published: 3 June 2015
(This article belongs to the Special Issue Prader-Willi Syndrome)
View Full-Text   |   Download PDF [640 KB, uploaded 3 June 2015]

Abstract

Prader-Willi syndrome (PWS) is a neurodevelopmental disorder caused by the absence of paternally expressed, imprinted genes on chromosome 15q11-13. Individuals with PWS characteristically have poor feeding and lack of appetite in infancy, followed by the development of weight gain and then uncontrolled appetite and lack of satiety, sometime after the age of two. The overwhelming drive to eat is coupled with reduced energy expenditure and decreased caloric requirements, thus, individuals with PWS will become severely obese unless their food intake is strictly controlled. The mechanisms underlying hyperphagia in PWS remain incompletely understood, and to date no drugs have proven effective in controlling appetite. However, clinical trials have started for several medications, which may provide therapeutic options for those with PWS. These medication trials may also provide insight into potential treatments for obesity in the general population. Ideally, these treatments will help alleviate the complex metabolic issues that are part of this syndrome. View Full-Text
Keywords: Prader-Willi syndrome; hyperphagia; drug trials; obesity Prader-Willi syndrome; hyperphagia; drug trials; obesity
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Miller, J.L.; Strong, T.V.; Heinemann, J. Medication Trials for Hyperphagia and Food-Related Behaviors in Prader–Willi Syndrome. Diseases 2015, 3, 78-85.

Show more citation formats Show less citations formats

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Diseases EISSN 2079-9721 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top